Zobrazeno 1 - 10
of 45
pro vyhledávání: '"C. Lobetti-Bodoni"'
Autor:
M. Dickinson, J. Martinez-Lopez, E. Jousseaume, C. Anjos, H. Yang, X. Chai, T. Wang, R. Ramos, C. Lobetti-Bodoni, S. Schuster, N. Fowler
Publikováno v:
HemaSphere, Vol 6, Pp 1001-1002 (2022)
Externí odkaz:
https://doaj.org/article/e758edab224244319070715586519b60
Autor:
T.S.K. Mok, J-L. Pujol, M. Tsuboi, J. Lee, E. Kim, O. Leonov, J. Zhang, J. Duan, C. Lobetti-Bodoni, J.C. Brase, A. Savchenko, P. Garrido Lopez
Publikováno v:
Annals of Oncology. 33:S1547-S1548
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0906e79e637f19527724464e9c55fb2c
https://doi.org/10.1016/j.annonc.2022.10.322
https://doi.org/10.1016/j.annonc.2022.10.322
Autor:
Richard W. Tsang, Gerasimos Pangalis, Andrés J.M. Ferreri, Andrea Janíková, Maria Elena Cabrera, G.S. Nowakowski, G. Ryan, Marek Trneny, Stefano Luminari, A. Ramirez, Silvia Montoto, Gianluca Gaidano, Emanuele Zucca, Massimo Federico, Carlo Visco, Armando López-Guillermo, Barbara Vannata, Annarita Conconi, Michael Mian, Igor Aurer, Barbara Pro, C Lobetti Bodoni, Luca Mazzucchelli
Publikováno v:
Hematological Oncology. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00daaa84ca58cd585948eba57e9c418c
https://doi.org/10.1002/hon.78_2879
https://doi.org/10.1002/hon.78_2879
Autor:
Andrés J.M. Ferreri, C Lobetti Bodoni, Monalisa Ghosh, Fritz Offner, Charalambos Andreadis, Pier Luigi Zinzani, Arne Kolstad, Martin Dreyling, Catherine Thieblemont, Julio C. Chavez, Stephen J. Schuster, P. Joy Ho, Piers Em Patten, Peter A. Riedell, Bastian von Tresckow, Marie José Kersten, Andreas Viardot, Leslie Popplewell, Ram Malladi, Aisha Masood, Michael Dickinson, Emmanuel Bachy, Joaquin Martinez-Lopez, Andreas L. Petzer, Aiesha Zia, Loretta J. Nastoupil, José A. Pérez-Simón, Hideo Harigae, Nathan Fowler, Takanori Teshima, Koji Kato, Jason Butler, Andy I. Chen, Joseph P. McGuirk
Publikováno v:
Blood. 138:131-131
Background: Follicular lymphoma is an indolent disease with a continuous relapsing pattern and typically requires multiple lines of therapy. Novel therapies such as tisagenlecleucel are being investigated to improve outcomes. Primary analysis of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f8aa838fb4add4d926b4460fd144981
https://doi.org/10.1182/blood-2021-145025
https://doi.org/10.1182/blood-2021-145025
Autor:
Catherine Thieblemont, Keith L. Davis, Sonali M. Smith, John Kuruvilla, Piers Em Patten, Carla Anjos, Joaquin Martinez-Lopez, Ana Isabel Jiminez Ubieto, Stephen J. Schuster, Martin Dreyling, Bastian von Tresckow, C Lobetti Bodoni, Nathan Fowler, Yucai Wang, Jufen Chu, Jie Zhang, Brian K. Link, Michael Dickinson, Luca Fischer, Gilles Salles
Publikováno v:
Blood. 138:3528-3528
Background: In the ELARA (E2202) trial (NCT03568461), tisagenlecleucel (tisa-cel) demonstrated high response rates in patients with relapsed/refractory follicular lymphoma (r/r FL), including those with high-risk disease, with an overall response rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::804f8155389df5fdba49b8b85957d4ee
https://doi.org/10.1182/blood-2021-149327
https://doi.org/10.1182/blood-2021-149327
Autor:
Yanni Hao, Lisa V. Hampson, Aisha Masood, Wen-Hsing Wu, Craig S Parzynski, C Lobetti Bodoni, Wei-Chun Hsu, Evgeny Degtyarev
Publikováno v:
Blood. 138:2419-2419
Introduction: In the single-arm phase 2 ELARA trial (NCT03568461), tisagenlecleucel demonstrated efficacy and favorable safety profile in patients with relapsed/refractory (r/r) follicular lymphoma (FL) after ≥ 2 lines of prior therapy, including i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::308a582646b6c0c4cb6fd2468e6e7664
https://doi.org/10.1182/blood-2021-147781
https://doi.org/10.1182/blood-2021-147781
Autor:
Luigia Monitillo, Rosalba Rosato, Marco Ladetto, F De Marco, C Lobetti Bodoni, R Calvi, Daniela Drandi, Monica Astolfi, Alberto Rocci, Roberto Francese, F Ficara, Mario Boccadoro, Andrea Gallamini, Sonia Vallet, Paola Omedè, Corrado Tarella, Irene Ricca, Carlo Marinone, Luciana Bergui, Mara Compagno
Some evidences suggest that telomere restriction fragment length (TRF-L) is an effective indicator of histopathogenesis in B-cell tumors. As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8532d2f51458dc6786afb42d4896c10c
http://hdl.handle.net/2318/35177
http://hdl.handle.net/2318/35177
Autor:
C, LOBETTI-BODONI
Publikováno v:
Clinica nuova; rassegna del progresso medico internazionale. 16(18-19)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9b636a958475f0716a220aa2e0055704
https://pubmed.ncbi.nlm.nih.gov/13116426
https://pubmed.ncbi.nlm.nih.gov/13116426
Publikováno v:
Seminar international. 8(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::571f4d5726d0dd3fa4980f39bbf6b78a
https://pubmed.ncbi.nlm.nih.gov/13646849
https://pubmed.ncbi.nlm.nih.gov/13646849
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.